A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

T. L. DeWeese, H. Van der Poel, S. Li, B. Mikhak, R. Drew, M. Goemann, U. Hamper, R. DeJong, N. Detorie, Ronald Rodriguez, T. Haulk, A. M. DeMarzo, S. Piantadosi, D. C. Yu, Y. Chen, D. R. Henderson, M. A. Carducci, W. G. Nelson, J. W. Simons

Research output: Contribution to journalArticle

318 Citations (Scopus)

Abstract

CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 × 1011 and 1 × 1013 viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan. The primary end point was the determination of treatment-related toxicity. Secondary objectives included evaluation of the antitumor activity of CV706 and monitoring for other correlates of antineoplastic action. In this study, CV706 was found to be safe and was not associated with irreversible grade 3 or any grade 4 toxicity. No grade > 1 alterations in liver function tests associated with CV706 administration were observed. Posttreatment prostatic biopsies and detection of a delayed "peak" of circulating copies of virus provided evidence of intraprostatic replication of CV706. The study defined the timing of CV706 shedding into blood and urine as well as the appearance of circulating Ad5 neutralizing antibodies. Finally, this study documents the serum PSA response of treated patients and reveals a dose response showing that all five patients who achieved a ≥50% reduction in PSA were treated with the highest two doses of CV706. This study represents the first clinical translation of a prostate-specific, replication-restricted adenovirus for the treatment of prostate cancer. Taken together, this study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data also suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.

Original languageEnglish (US)
Pages (from-to)7464-7472
Number of pages9
JournalCancer Research
Volume61
Issue number20
StatePublished - Oct 15 2001
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Adenoviridae
Prostatic Neoplasms
Radiotherapy
Endpoint Determination
Therapeutics
Liver Function Tests
Neutralizing Antibodies
Serum
Heterografts
Virion
Antineoplastic Agents
Prostate
Urine
Viruses
Biopsy
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DeWeese, T. L., Van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., ... Simons, J. W. (2001). A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research, 61(20), 7464-7472.

A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. / DeWeese, T. L.; Van der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, Ronald; Haulk, T.; DeMarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W.

In: Cancer Research, Vol. 61, No. 20, 15.10.2001, p. 7464-7472.

Research output: Contribution to journalArticle

DeWeese, TL, Van der Poel, H, Li, S, Mikhak, B, Drew, R, Goemann, M, Hamper, U, DeJong, R, Detorie, N, Rodriguez, R, Haulk, T, DeMarzo, AM, Piantadosi, S, Yu, DC, Chen, Y, Henderson, DR, Carducci, MA, Nelson, WG & Simons, JW 2001, 'A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy', Cancer Research, vol. 61, no. 20, pp. 7464-7472.
DeWeese, T. L. ; Van der Poel, H. ; Li, S. ; Mikhak, B. ; Drew, R. ; Goemann, M. ; Hamper, U. ; DeJong, R. ; Detorie, N. ; Rodriguez, Ronald ; Haulk, T. ; DeMarzo, A. M. ; Piantadosi, S. ; Yu, D. C. ; Chen, Y. ; Henderson, D. R. ; Carducci, M. A. ; Nelson, W. G. ; Simons, J. W. / A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. In: Cancer Research. 2001 ; Vol. 61, No. 20. pp. 7464-7472.
@article{a6e2f8b71a6f45ba8a2f9bf6c30140cc,
title = "A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy",
abstract = "CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 × 1011 and 1 × 1013 viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan. The primary end point was the determination of treatment-related toxicity. Secondary objectives included evaluation of the antitumor activity of CV706 and monitoring for other correlates of antineoplastic action. In this study, CV706 was found to be safe and was not associated with irreversible grade 3 or any grade 4 toxicity. No grade > 1 alterations in liver function tests associated with CV706 administration were observed. Posttreatment prostatic biopsies and detection of a delayed {"}peak{"} of circulating copies of virus provided evidence of intraprostatic replication of CV706. The study defined the timing of CV706 shedding into blood and urine as well as the appearance of circulating Ad5 neutralizing antibodies. Finally, this study documents the serum PSA response of treated patients and reveals a dose response showing that all five patients who achieved a ≥50{\%} reduction in PSA were treated with the highest two doses of CV706. This study represents the first clinical translation of a prostate-specific, replication-restricted adenovirus for the treatment of prostate cancer. Taken together, this study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data also suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.",
author = "DeWeese, {T. L.} and {Van der Poel}, H. and S. Li and B. Mikhak and R. Drew and M. Goemann and U. Hamper and R. DeJong and N. Detorie and Ronald Rodriguez and T. Haulk and DeMarzo, {A. M.} and S. Piantadosi and Yu, {D. C.} and Y. Chen and Henderson, {D. R.} and Carducci, {M. A.} and Nelson, {W. G.} and Simons, {J. W.}",
year = "2001",
month = "10",
day = "15",
language = "English (US)",
volume = "61",
pages = "7464--7472",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

AU - DeWeese, T. L.

AU - Van der Poel, H.

AU - Li, S.

AU - Mikhak, B.

AU - Drew, R.

AU - Goemann, M.

AU - Hamper, U.

AU - DeJong, R.

AU - Detorie, N.

AU - Rodriguez, Ronald

AU - Haulk, T.

AU - DeMarzo, A. M.

AU - Piantadosi, S.

AU - Yu, D. C.

AU - Chen, Y.

AU - Henderson, D. R.

AU - Carducci, M. A.

AU - Nelson, W. G.

AU - Simons, J. W.

PY - 2001/10/15

Y1 - 2001/10/15

N2 - CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 × 1011 and 1 × 1013 viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan. The primary end point was the determination of treatment-related toxicity. Secondary objectives included evaluation of the antitumor activity of CV706 and monitoring for other correlates of antineoplastic action. In this study, CV706 was found to be safe and was not associated with irreversible grade 3 or any grade 4 toxicity. No grade > 1 alterations in liver function tests associated with CV706 administration were observed. Posttreatment prostatic biopsies and detection of a delayed "peak" of circulating copies of virus provided evidence of intraprostatic replication of CV706. The study defined the timing of CV706 shedding into blood and urine as well as the appearance of circulating Ad5 neutralizing antibodies. Finally, this study documents the serum PSA response of treated patients and reveals a dose response showing that all five patients who achieved a ≥50% reduction in PSA were treated with the highest two doses of CV706. This study represents the first clinical translation of a prostate-specific, replication-restricted adenovirus for the treatment of prostate cancer. Taken together, this study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data also suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.

AB - CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 × 1011 and 1 × 1013 viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan. The primary end point was the determination of treatment-related toxicity. Secondary objectives included evaluation of the antitumor activity of CV706 and monitoring for other correlates of antineoplastic action. In this study, CV706 was found to be safe and was not associated with irreversible grade 3 or any grade 4 toxicity. No grade > 1 alterations in liver function tests associated with CV706 administration were observed. Posttreatment prostatic biopsies and detection of a delayed "peak" of circulating copies of virus provided evidence of intraprostatic replication of CV706. The study defined the timing of CV706 shedding into blood and urine as well as the appearance of circulating Ad5 neutralizing antibodies. Finally, this study documents the serum PSA response of treated patients and reveals a dose response showing that all five patients who achieved a ≥50% reduction in PSA were treated with the highest two doses of CV706. This study represents the first clinical translation of a prostate-specific, replication-restricted adenovirus for the treatment of prostate cancer. Taken together, this study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data also suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.

UR - http://www.scopus.com/inward/record.url?scp=0035887153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035887153&partnerID=8YFLogxK

M3 - Article

C2 - 11606381

AN - SCOPUS:0035887153

VL - 61

SP - 7464

EP - 7472

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -